查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
青光眼市場規模/佔有率/趨勢分析報告：按疾病類型、按藥物類別、按配銷通路、按地區、細分市場趨勢，2023-2030
市場調查報告書
商品編碼
1321347

青光眼市場規模/佔有率/趨勢分析報告：按疾病類型、按藥物類別、按配銷通路、按地區、細分市場趨勢，2023-2030

Glaucoma Market Size, Share & Trends Analysis Report By Disease Type (Open Angle Glaucoma, Angle Closure Glaucoma), By Drug Class (Prostaglandins Analogs, Beta-blockers), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

青光眼市場成長和趨勢

Grand View Research, Inc.最新報告顯示，預計2023年至2030年全球青光眼市場規模將以4.61%的年複合成長率成長，2030年將達到115.2億美元。

青光眼患病率的上升、個性化治療策略的採用以及患者意識的提高正在推動市場的成長。以患者為中心的護理在疾病治療中變得越來越重要。這包括自我管理、患者教育和協作決策等技術。通過教育患者並讓患者參與治療選擇，患者對治療的依從性、治療滿意度和總體結果均得到改善。

青光眼行業擁有強大的產品線，預計將推動未來的成長。例如，據 2023 年 4 月《科學進展雜誌》報導，科學家正在開發新的基因療法來治療這種疾病。 Exhaura Ltd 和 Smurfit 遺傳學研究所合作開發了該產品。支持新型療法開發的研發團隊的存在預計將推動市場成長。例如，2023年3月，印第安納大學醫學院宣布其眼科正在致力於利用誘導多能幹細胞來幫助治療青光眼。

此外，人口失明發生率的增加使得更多的人選擇早期治療，從而推動了該行業的成長。例如，根據世界衛生組織（WHO）2020年發布的報告，青光眼是僅次於白內障的第二大致盲眼病。據報導，印度有 1190 萬人因青光眼而失明。視力喪失的負擔日益加重，導致對治療藥物和生物製劑的需求增加，推動行業成長。

患有糖尿病、年齡相關性黃斑部病變（AMD）、白內障和乾眼症等眼科疾病的患者更容易患上青光眼。因此，罹患眼科疾病的老年人口不斷增加正在推動對青光眼藥物的需求。此外，主要企業正在努力通過推出用於治療這種疾病的新產品來擴大產品系列。例如，2021年3月，Teva Pharmaceuticals USA, Inc.宣佈在美國推出首個學名藥1% AZOPT（布林佐胺滴眼液）。本品用於治療開放性青光眼和高眼壓症引起的眼壓升高。

青光眼市場報告亮點

  • 按疾病類型分類，由於治療性生物製劑的市場發展，開放性青光眼細分市場將在 2022 年佔據主導地位。
  • 按藥物類別分類，前列腺素類似物在 2022 年佔據最大的市場佔有率。
  • 按配銷通路分類，2022年醫院藥房領域佔據最大市場佔有率。醫院藥房使患者受益，因為它們易於使用並提供合格的指導。
  • 北美地區佔據強大的區域地位，2022 年市場佔有率為 38.60%。這是由於政府資助增加和治療採用率提高而導致該地區研發活動成長的結果。
  • 主要參與企業包括輝瑞、參天、諾華、愛爾康、阿克倫營運公司、Thea Pharma、艾伯維、博士倫和梯瓦製藥工業公司。

目錄

第1章 調查方法和範圍

  • 市場區隔
  • 目的
  • 調查方法
  • 資訊採購
    • 購買數據庫
    • GVR內部數據庫
    • 次要資訊
    • 初步調查
  • 資訊或資料分析
    • 資料分析模型
  • 市場形成和檢驗
  • 型號詳情
    • 產品流向分析
  • 二手資訊清單
  • 簡稱列表
  • 主要資訊清單

第2章 執行摘要

第3章 市場變量、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系預測
    • 母公司市場預測
    • 相關/輔助市場預測
  • 市場動態
  • 市場促進因素
    • 加強行業主要企業之間的協作和夥伴關係
    • 推出創新產品
    • 加強眼科領域的研究和開發
  • 市場抑制因素分析
    • 對疾病缺乏認知和診斷不足
    • 昂貴的治療費用
  • 營商環境分析
    • SWOT 分析：按因素（政治/法律、經濟/技術）
    • 波特五力分析
    • COVID-19 影響分析

第4章 疾病業務分析

  • 青光眼市場：疾病類型變化分析
  • 開放性青光眼
    • 開放性青光眼市場，2018-2030
  • 隅角閉鎖性青光眼
    • 2018-2030 年隅角閉鎖性青光眼市場
  • 其他

第5章 醫藥類業務分析

  • 青光眼市場：藥物類別變化分析
  • 前列腺素類似物市場，2018-2030
  • BETA 受體阻斷藥
  • 腎上腺素能激動劑
  • 碳酸酐酶抑製劑
  • 其他

第6章 配銷通路業務分析

  • 青光眼市場：配銷通路波動分析
  • 醫院藥房
  • 零售藥房
  • 網上藥房

第7章 區域業務分析

  • 2022 年和 2030 年青光眼市場佔有率（按地區）
  • 北美
    • 北美青光眼市場，2018-2030
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲青光眼市場，2018-2030
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區青光眼市場，2018-2030
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳大利亞
    • 鯛魚
  • 拉丁美洲
    • 拉丁美洲青光眼市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 中東和非洲青光眼市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭形勢

  • 參與企業概況
  • 財務績效
  • 參與企業
    • 市場領導者
    • 2022 年青光眼市場佔有率分析
    • 公司簡介
    • 戰略規劃
Product Code: GVR-4-68040-095-0

Glaucoma Market Growth & Trends

The global glaucoma market size is expected to reach USD 11.52 billion by 2030, expanding at a CAGR of 4.61% from 2023 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of glaucoma, incorporation of individualized treatment strategies and growing patient awareness are driving the market growth. Patient-centered care is becoming increasingly important for the treatment of the disease. This covers techniques for self-management, patient education, and collaborative decision-making. Patients' adherence to treatments, contentment with them, and overall outcomes can all be enhanced by educating them and including them in treatment choices.

The glaucoma industry has a strong pipeline, which is anticipated to fuel future growth. For instance, as per Science Advances Journal in April 2023, scientists are developing a novel gene therapy to treat the disease. The collaboration of Exhaura Ltd and Smurfit Institute of Genetics is developing this product. The presence of research and development teams supporting the development of novel treatments is projected to propel market growth. For instance, in March 2023, IU School of Medicine announced its Department of Opthalmology is working on using induced pluripotent stem cells to aid glaucoma treatment.

Moreover, the increasing incidence of blindness among the population is propelling the industry growth as the more aware population opts for early treatment. For instance, as per the reports published by World Health Organization in 2020, glaucoma was the second major cause of blindness after cataracts. India reported 11.9 million cases of glaucoma-associated blindness. The increasing burden of vision loss led to the increasing demand for therapeutics and biologics, which boosts the industry growth.

Patients with diabetes and other eye conditions, such as Age-related Macular Degeneration (AMD), cataract, and dry eye, are more prone to developing glaucoma. Thus, the growing elderly population, which is highly susceptible to eye diseases is propelling the demand for glaucoma drugs. Moreover, key players are involved in product portfolio expansion with the launch of novel products used to treat the disease. For instance, in March 2021, Teva Pharmaceuticals USA, Inc. announced the launch of the first generic version of 1% AZOPT (brinzolamide ophthalmic solution) in the U.S., which is used to treat high levels of pressure inside the eye caused due to open-angle glaucoma and ocular hypertension.

Glaucoma Market Report Highlights

  • By disease type, the open-angle glaucoma segment dominated the market in 2022 owing to the development of biologics for the treatment of the disease
  • By drug class, the prostaglandin analogs segment held the largest market share in 2022, attributable to their safety and universal acceptance as the first-line treatment option
  • By distribution channel, the hospital pharmacy segment held the largest market share in 2022. The patients benefit from the hospital pharmacy as it provides accessibility and qualified guidance
  • North America has established a strong regional position with a 38.60% market share in 2022. This is a result of the region's R&D activity growing due to increased government funding and a high adoption rate of treatments
  • A few of the key industry players include Pfizer Inc.; Santen Pharmaceutical Co., Ltd.; Novartis AG; Alcon Inc.; Akron Operating Company LLC; Thea Pharma; AbbVie, Inc.; Bausch & Lomb Incorporated; and Teva Pharmaceuticals Industries Ltd.

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. List Of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Disease Type And Drug Class Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Increasing Collaboration And Partnerships Among The Industry's Key Players
    • 3.4.2. Novel Product Launch
    • 3.4.3. Increasing R&D In The Ophthalmology Sector
  • 3.5. Market Restraint Analysis
    • 3.5.1. Lack Of Awareness And Underdiagnoses Of The Disease
    • 3.5.2. High Cost Of The Treatment
  • 3.6. Business Environment Analysis
    • 3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. Covid-19 Impact Analysis

Chapter 4. Disease Type Business Analysis

  • 4.1. Glaucoma Market: Disease Type Movement Analysis
  • 4.2. Open Angle Glaucoma
    • 4.2.1. Open Angle Glaucoma Market, 2018 - 2030 (USD Million)
  • 4.3. Angle Closure Glaucoma
    • 4.3.1. Angle Closure Glaucoma Market, 2018 - 2030 (USD Million)
  • 4.4. Others
    • 4.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Drug Class Business Analysis

  • 5.1. Glaucoma Market: Drug Class Movement Analysis
  • 5.2. Prostaglandins Analogs Market, 2018 - 2030 (USD Million)
  • 5.3. Beta-Blockers
    • 5.3.1. Beta-Blockers Market, 2018 - 2030 (USD Million)
  • 5.4. Adrenergic Agonists
    • 5.4.1. Adrenergic Agonists Market, 2018 - 2030 (USD Million)
  • 5.5. Carbonic Anhydrase Inhibitors
    • 5.5.1. Carbonic Anhydrase Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Glaucoma Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacy
    • 6.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacy
    • 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.4. Online Pharmacy
    • 6.4.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Glaucoma Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target Disease Prevalence
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement Scenario
      • 7.2.2.6. U.S. Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
      • 7.2.3.6. Canada Glaucoma Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
      • 7.3.2.6. Germany Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.3. Uk
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
      • 7.3.3.6. Uk Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
      • 7.3.4.6. France Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Italy Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Spain Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. Denmark Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Sweden Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Norway Glaucoma Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
      • 7.4.2.6. Japan Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
      • 7.4.3.6. China Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
      • 7.4.4.6. India Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. South Korea Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. Australia Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Thailand Glaucoma Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
      • 7.5.2.6. Brazil Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
      • 7.5.3.6. Mexico Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Regulatory Framework
      • 7.5.4.5. Reimbursement Scenario
      • 7.5.4.6. Argentina Glaucoma Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
      • 7.6.2.6. South Africa Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
      • 7.6.3.6. Saudi Arabia Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
      • 7.6.4.6. UAE Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. Kuwait Glaucoma Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant's Overview
  • 8.2. Financial Performance
  • 8.3. Participant Categorization
    • 8.3.1. Market Leaders
    • 8.3.2. Glaucoma Market Share Analysis, 2022
    • 8.3.3. Company Profiles
      • 8.3.3.1. Pfizer Inc.
      • 8.3.3.1.1. Company Overview
      • 8.3.3.1.2. Financial Performance
      • 8.3.3.1.3. Product Benchmarking
      • 8.3.3.1.4. Strategic Initiatives
      • 8.3.3.2. Santen Pharmaceutical Co., Ltd.
      • 8.3.3.2.1. Company Overview
      • 8.3.3.2.2. Financial Performance
      • 8.3.3.2.3. Product Benchmarking
      • 8.3.3.2.4. Strategic Initiatives
      • 8.3.3.3. Novartis Ag
      • 8.3.3.3.1. Company Overview
      • 8.3.3.3.2. Financial Performance
      • 8.3.3.3.3. Product Benchmarking
      • 8.3.3.3.4. Strategic Initiatives
      • 8.3.3.4. Akron Operating Company Llc
      • 8.3.3.4.1. Company Overview
      • 8.3.3.4.2. Financial Performance
      • 8.3.3.4.3. Product Benchmarking
      • 8.3.3.4.4. Strategic Initiatives
      • 8.3.3.5. Thea Pharma
      • 8.3.3.5.1. Company Overview
      • 8.3.3.5.2. Financial Performance
      • 8.3.3.5.3. Product Benchmarking
      • 8.3.3.5.4. Strategic Initiatives
      • 8.3.3.6. Abbvie, Inc.
      • 8.3.3.6.1. Company Overview
      • 8.3.3.6.2. Financial Performance
      • 8.3.3.6.3. Product Benchmarking
      • 8.3.3.6.4. Strategic Initiatives
      • 8.3.3.7. Bausch + Lomb Corporation
      • 8.3.3.7.1. Company Overview
      • 8.3.3.7.2. Financial Performance
      • 8.3.3.7.3. Product Benchmarking
      • 8.3.3.7.4. Strategic Initiatives
      • 8.3.3.8. Teva Pharmaceuticals Industries Ltd.
      • 8.3.3.8.1. Company Overview
      • 8.3.3.8.2. Financial Performance
      • 8.3.3.8.3. Product Benchmarking
      • 8.3.3.8.4. Strategic Initiatives
      • 8.3.3.9. Alcon Inc.
      • 8.3.3.9.1. Company Overview
      • 8.3.3.9.2. Financial Performance
      • 8.3.3.9.3. Product Benchmarking
      • 8.3.3.9.4. Strategic Initiatives
    • 8.3.4. Strategy Mapping
      • 8.3.4.1. Expansion
      • 8.3.4.2. Acquisition
      • 8.3.4.3. Collaborations
      • 8.3.4.4. Disease Type/Drug Class Launch
      • 8.3.4.5. Partnerships
      • 8.3.4.6. Others

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 3 Global Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 4 Global Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 Global Glaucoma Market, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Glaucoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 8 North America Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9 North America Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 U.S. Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Canada Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Glaucoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 19 Europe Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Germany Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 22 Germany Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 UK Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 24 UK Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 25 UK Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 France Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 27 France Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 28 France Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Italy Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 31 Italy Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Spain Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 34 Spain Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Denmark Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 37 Denmark Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Sweden Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 40 Sweden Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Norway Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 43 Norway Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Glaucoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 China Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 49 China Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 50 China Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Japan Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 53 Japan Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 India Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 55 India Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 56 India Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 South Korea Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 59 South Korea Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Australia Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 62 Australia Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Thailand Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 65 Thailand Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Latin America Glaucoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 67 Latin America Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 69 Latin America Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 Brazil Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 72 Brazil Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Mexico Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 75 Mexico Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 78 Argentina Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 83 South Africa Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 85 South Africa Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 UAE Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 91 UAE Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Glaucoma Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2022
  • Fig. 16 Global Glaucoma Market: Disease Type Movement Analysis
  • Fig. 17 Global Glaucoma Market, by Open Angle Glaucoma, 2018 - 2030 (USD Million)
  • Fig. 18 Global Glaucoma Market, by Angle Closure Glaucoma, 2018 - 2030 (USD Million)
  • Fig. 19 Global Glaucoma Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 20 Global Glaucoma Market: Drug Class Movement Analysis
  • Fig. 21 Global Glaucoma Market, by Prostaglandins Analogs, 2018 - 2030 (USD Million)
  • Fig. 22 Global Glaucoma Market, by Beta-blockers, 2018 - 2030 (USD Million)
  • Fig. 23 Global Glaucoma Market, by Adrenergic Agonists, 2018 - 2030 (USD Million)
  • Fig. 24 Global Glaucoma Market, by Carbonic Anhydrase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 25 Global Glaucoma Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 26 Global Glaucoma Market: Distribution Channel Movement Analysis
  • Fig. 27 Global Glaucoma Market, by Hospital Pharmacy 2018 - 2030 (USD Million)
  • Fig. 28 Global Glaucoma Market, by Retail Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 29 Global Glaucoma Market, by Online Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 30 Regional Marketplace: Key Takeaways
  • Fig. 31 Regional Outlook, 2022 & 2030
  • Fig. 32 Global Glaucoma Market: Region Movement Analysis
  • Fig. 33 North America Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 38 UK Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 39 France Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 41 Spain Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 46 Japan Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 47 China Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 48 India Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 49 Australia Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 59 UAE Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait Glaucoma Market, 2018 - 2030 (USD Million)